The Prediction of a 3-Protein-Based Model on the Prognosis of Head and Neck Squamous Cell Carcinoma

Table 1

Clinical data of patients in the training set and testing set.

Variates	Total ()	Training set; ()	Testing set; ()	value	Method
Age, years				0.379	test
Gender
Female	93 (28.01%)	50 (29.76%)	43 (26.22%)	0.472	test
Male	239 (71.99%)	118 (70.24%)	121 (73.78%)
Stage
I	14 (4.22%)	8 (4.76%)	6 (3.66%)	0.112	test
II	57 (17.17%)	35 (20.83%)	22 (13.41%)
III	61 (18.37%)	24 (14.29%)	37 (22.56%)
IV	200 (60.24%)	101 (60.12%)	99 (60.37%)
T stage
1	23 (6.93%)	10 (5.95%)	13 (7.93%)	0.070	test
2	99 (29.82%)	61 (36.31%)	38 (23.17%)
3	83 (25.00%)	37 (22.02%)	46 (28.05%)
4	127 (38.25%)	60 (35.71%)	67 (40.85%)
N stage
0	150 (45.18%)	75 (44.64%)	75 (45.73%)	0.472	Fisher’s exact test
1	44 (13.25%)	18 (10.71%)	26 (15.85%)
2	131 (39.46%)	71 (42.26%)	60 (36.59%)
3	7 (2.11%)	4 (2.38%)	3 (1.83%)
M stage
0	330 (99.40%)	167 (99.40%)	163 (99.39%)	0.745	Fisher’s exact test
1	2 (0.60%)	1 (0.60%)	1 (0.61%)
Smoking history
Nonsmoker	124 (37.35%)	62 (36.90%)	62 (37.80%)	0.865	test
Smoker	208 (62.65%)	106 (63.10%)	102 (62.20%)
Survival time (mean), units				0.523	test
Survival status
Alive	203 (61.14%)	104 (61.90%)	99 (60.37%)	0.774	test
Dead	129 (38.86%)	64 (38.10%)	65 (39.63%)

Survival time and age presented as and other data as count (percentage).